Eric Lu, MD

Just a budding hematologist trying to get through fellowship one dry tap at a time

[Eric Lu, MD @drytaps]

@jlberrymd Nice thread. Given each step from frontline metastatic —> 3L+ therapy corresponds with lower ORR and also with poorer PS, I imagine in later lines of therapy, the marginal benefits seen in trials with PS 0-2 are probably erased with PS 3-4. But worth considering in frontline

[Eric Lu, MD @drytaps]

"Doing everything" from the provider's standpoint includes having the honest discussion #HOJournalClub

[Vinay Prasad MD MPH @VPrasadMDMPH]

@RyanNguyenDO @DevikaDasMD @amarkelkar @HOJournalClub A wise oncologist taught me that it is easy to give more chemotherapy, it is hard to have an honest conversation #HOJournalClub

And that is the root of so much suffering

[Eric Lu, MD @drytaps]

@VPrasadMDMPH @HOJournalClub @GlendaDelgadoR OS is 2ndary endpoint in POLO (data 46% mature), but given the control arm and generalizability of trial, even if significant OS diff, not sure how to incorporate olaparib in panc. I guess question is IF/WHEN olaparib can be used in BRCA+panc and how to study? #HOJournalClub

[Eric Lu, MD @drytaps]

@AkivaDiamond @VPrasadMDMPH @arkhaki @amarkelkar @HOJournalClub Let's hope that's not the case for most trials, esp seeing as 2:1 is more common than 3:2 schemes these days... hah #HOJournalClub

[Eric Lu, MD @drytaps]

@HOJournalClub @VPrasadMDMPH Surrogate endpoint (tumor smaller on CT) + clinical endpoint (mortality) = still surrogate endpoint? #HOJournalClub

[Eric Lu, MD @drytaps]

@HOJournalClub @VPrasadMDMPH I think whenever there is a line such as "IMspire150 was a randomised... study done at 112 institutes in 20 countries" one has to carefully examine what was the next line therapy given to those in experimental vs control arm (esp if its reflective of current US practice)

[Eric Lu, MD @drytaps]

@VPrasadMDMPH @HOJournalClub So there was a mandatory washout time / treatment interval of 4-8 weeks.
RR was 23% in olaparib group and 12% in placebo group. I suppose you could get some RR in the form of placebo but one wonders if there is residual FOLFIRINOX effect? #HOJournalClub

[Eric Lu, MD @drytaps]

@DevikaDasMD @HOJournalClub @VPrasadMDMPH Seems like generalizability to clinical practice will be limited. Likely will be a difference between population that was studied vs what it will be marketed as / extrapolated to in clinical practice. #HOJournalClub

[Eric Lu, MD @drytaps]

@HOJournalClub @VPrasadMDMPH Echoing what others are saying here. Table 1 shows that 50% of patients had stable disease following frontline chemotherapy. Odd that these are then randomized to more treatment (olaparib, which is presumably active as a monotherapy here) vs no further treatment

#HOJournalClub

[Eric Lu, MD @drytaps]

@HOJournalClub @VPrasadMDMPH @DocLHenry @DevikaDasMD @DrMMurphy @LoyolaOnc @HemeOncGators @UABHemOncFellow @NarjustDumaMD @montypal @marklewismd @HemOncWomenDocs How can we tune in to this meeting? Is there a zoom link?

[Eric Lu, MD @drytaps]

@DGlaucomflecken The bone marrow...?

[Eric Lu, MD @drytaps]

@austinperlmd Excellent public health opportunity to offer carrots instead

[Eric Lu, MD @drytaps]

@Svematologist Unlike the other thrombophilias... it changes management if you find it... so...

[Eric Lu, MD @drytaps]

@OHSUIMRes @PDX_Tom @aoglasser @Bloodman @joelb_pdx @rloganjonesmd @kelsi_manley @DesaisSima A positive, collegial learning environment across multiple subspecialties. And this unreal sunrise view after night float. Miss you guys!

[Eric Lu, MD @drytaps]

@StefanKertesz The two may not be mutually exclusive!

[Eric Lu, MD @drytaps]

You know your talk is going well when you spot multiple people in the audience taking low quality, image zoomed phone pics of your slides

[Eric Lu, MD @drytaps]

✅Research mentor / my first consult oncology attending as an intern / attendee with coolest hair #ASCOiSPY #ASCO19

[Eric Lu, MD @drytaps]

@LoewenthalMd Also near impossible to hear korotkoff sounds for BP...!

[Eric Lu, MD @drytaps]

So many medicine pearls that resonate w/ me here. Can we please stop treating inpatient HTN “urgency?”

[Eric Lu, MD @drytaps]

@kelsi_manley @rloganjonesmd Excellent viewpoint from the patient family angle. Will bookmark